[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1252173A1 - 用於純化絲氨酸蛋白酶的方法 - Google Patents

用於純化絲氨酸蛋白酶的方法

Info

Publication number
HK1252173A1
HK1252173A1 HK18111574.1A HK18111574A HK1252173A1 HK 1252173 A1 HK1252173 A1 HK 1252173A1 HK 18111574 A HK18111574 A HK 18111574A HK 1252173 A1 HK1252173 A1 HK 1252173A1
Authority
HK
Hong Kong
Prior art keywords
purification
methods
serine proteases
proteases
serine
Prior art date
Application number
HK18111574.1A
Other languages
English (en)
Inventor
Anjali Pandey
Jack W Rose
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of HK1252173A1 publication Critical patent/HK1252173A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6432Coagulation factor Xa (3.4.21.6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804Affinity chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
HK18111574.1A 2012-12-27 2018-09-07 用於純化絲氨酸蛋白酶的方法 HK1252173A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261746544P 2012-12-27 2012-12-27
US13/830,372 US9200268B2 (en) 2012-12-27 2013-03-14 Compounds and methods for purification of serine proteases

Publications (1)

Publication Number Publication Date
HK1252173A1 true HK1252173A1 (zh) 2019-05-17

Family

ID=51017611

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16104212.6A HK1216252A1 (zh) 2012-12-27 2016-04-13 純化絲氨酸蛋白酶的化合物和方法
HK18111574.1A HK1252173A1 (zh) 2012-12-27 2018-09-07 用於純化絲氨酸蛋白酶的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16104212.6A HK1216252A1 (zh) 2012-12-27 2016-04-13 純化絲氨酸蛋白酶的化合物和方法

Country Status (11)

Country Link
US (1) US9200268B2 (zh)
EP (2) EP3293175B1 (zh)
AU (1) AU2013370215B9 (zh)
CA (1) CA2896512C (zh)
ES (1) ES2907133T3 (zh)
HK (2) HK1216252A1 (zh)
IL (1) IL239208B (zh)
NZ (1) NZ709541A (zh)
SG (1) SG11201504339TA (zh)
WO (1) WO2014106128A1 (zh)
ZA (2) ZA201505200B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CN106831498B (zh) * 2017-01-12 2018-10-30 广州润坤生物科技有限公司 呋喃西林代谢物sem衍生化半抗原、人工抗原的制备方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
DE60040676D1 (de) * 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
ATE311366T1 (de) 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
EP1373194B1 (en) * 2001-03-30 2007-08-01 Millennium Pharmaceuticals, Inc. BENZAMIDE INHIBITORS OF FACTOR Xa
CA2541809A1 (en) * 2003-10-09 2005-04-21 Millennium Pharmaceuticals, Inc. Thioether-substituted benzamides as inhibitors of factor xa
ATE457302T1 (de) * 2004-11-24 2010-02-15 Lilly Co Eli Aromatische etherderivate als thrombin-hemmer
EP2431358A1 (en) 2005-11-08 2012-03-21 Millennium Pharmaceuticals, Inc. Method of preparing a factor XA inhibitor
WO2008057972A1 (en) 2006-11-02 2008-05-15 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
CA2671502C (en) * 2006-12-08 2017-01-24 Millennium Pharmaceuticals, Inc. Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
EA020531B1 (ru) 2007-04-13 2014-11-28 Милленниум Фармасьютикалз, Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИКОАГУЛИРУЮЩЕГО СРЕДСТВА С СОЕДИНЕНИЕМ, КОТОРОЕ ДЕЙСТВУЕТ КАК ИНГИБИТОР ФАКТОРА Ха
JP5439363B2 (ja) 2007-05-02 2014-03-12 ポートラ ファーマシューティカルズ, インコーポレイテッド 血小板adp受容体阻害剤として作用する化合物による併用療法
CA2697583C (en) 2007-09-28 2016-04-12 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
EP2414517B1 (en) 2009-03-30 2016-09-21 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
WO2010127980A1 (en) 2009-05-05 2010-11-11 F. Hoffmann-La Roche Ag Fret-based binding assay
WO2011084519A1 (en) 2009-12-17 2011-07-14 Millennium Pharmaceuticals, Inc. Methods of synthesizing factor xa inhibitors
TW201240664A (en) 2010-09-01 2012-10-16 Portola Pharm Inc Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor
AR082804A1 (es) 2010-09-01 2013-01-09 Portola Pharm Inc Formas cristalinas de un inhibidor del factor xa
US20130230901A1 (en) 2012-02-14 2013-09-05 Portola Pharmaceuticals, Inc. Process for making recombinant antidote to factor xa inhibitor
CA2876361C (en) 2012-06-14 2020-06-30 Portola Pharmaceuticals, Inc. Method for purification of recombinant factor xa derivatives

Also Published As

Publication number Publication date
CA2896512C (en) 2021-09-14
ZA201800077B (en) 2019-08-28
NZ709541A (en) 2019-01-25
HK1216252A1 (zh) 2016-10-28
IL239208A0 (en) 2015-07-30
ZA201505200B (en) 2022-09-28
EP3293175A1 (en) 2018-03-14
WO2014106128A1 (en) 2014-07-03
AU2013370215B9 (en) 2018-04-19
IL239208B (en) 2018-07-31
EP2938596B1 (en) 2017-11-01
US9200268B2 (en) 2015-12-01
AU2013370215A1 (en) 2015-07-16
AU2013370215B2 (en) 2018-04-05
EP3293175B1 (en) 2021-12-01
ES2907133T3 (es) 2022-04-22
SG11201504339TA (en) 2015-07-30
CA2896512A1 (en) 2014-07-03
US20140186923A1 (en) 2014-07-03
EP2938596A1 (en) 2015-11-04

Similar Documents

Publication Publication Date Title
IL287057A (en) Purified iduronate-2-sulfatase
ZA201305971B (en) Method for the purification of biphephos
IL225650A0 (en) Protein purification processes
HK1216429A1 (zh) 用於純化芳基硫酸酯酶 的方法
HRP20190123T1 (hr) Postupak pročišćavanja saponina
SG11201403891SA (en) Purification of flaviviruses
HK1196362A1 (zh) 作為蛋白酶抑制劑的大環酰胺
SG11201406800UA (en) Purification of air
PL2776452T3 (pl) Sposób oczyszczania teikoplaniny
PL2934172T3 (pl) Sposób oczyszczania lecytyny
HK1252173A1 (zh) 用於純化絲氨酸蛋白酶的方法
ZA201404831B (en) Treatment of surfactant laden wastewater
HK1201277A1 (zh) 用於製備 蛋白酶抑制劑的方法
HK1197229A1 (zh) 製備蛋白酶抑制劑的方法
PL2776453T3 (pl) Sposób oczyszczania teikoplaniny
AU2011900234A0 (en) Serine protease inhibitors